Skip to content

Selecta (NASDAQ: SELB), founded in 2008, is a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPā„¢) to a range of biologics for rare and serious diseases that require new treatment options.

Latest Press from Selecta Biosciences

Next